Evidence map›Paper›PMID 38087481›Full record

ArticleBMJ case reports2023

SARS-CoV-2 in an immunocompromised host: convalescent plasma therapy and viral evolution elucidated by whole genome sequencing.

Helena Seth-Smith, Silvan Vesenbeckh, Adrian Egli, Sebastian Ott

Registry-linked trialAbstract readCase Reports
In one paragraph

Article in BMJ case reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04351503 (A Systems Approach to Predict the Outcome of SARS-CoV-2 in the Population of a City), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04351503 completednot on this map

A Systems Approach to Predict the Outcome of SARS-CoV-2 in the Population of a City

TypeobservationalSponsorUniversity Hospital, Basel, SwitzerlandRan2020 to 2022Enrolled126,586ConditionsSARS Coronavirus (SARS-CoV-2) InfectionArmsStudy A, Study B, Study C, Study D
3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Helena Seth-Smith *Institute of Medical Microbiology, University of Zurich, Zurich, Switzerland.ORCID http://orcid.org/0000-0002-6082-5114
Silvan Vesenbeckh *Department of Pulmonology, University Hospital Zurich, Zurich, Switzerland SilvanManuel.Vesenbeckh@usz.ch.
Adrian Egli *Institute of Medical Microbiology, University of Zurich, Zurich, Switzerland.
Sebastian Ott *Department of Pulmonology, Sankt Claraspital, Basel, Switzerland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The evolution of SARS-CoV-2 within immunocompromised hosts who fail to clear the virus over many months has been proposed as a route to the development of Variants of Concern (VoCs). We present a case of an immunocompromised male patient with a prolonged SARS-CoV-2 infection. During hospitalisation, 7 weeks after first diagnosis, his condition worsened to require continuous ventilation support. Resolution of symptoms was observed after convalescent plasma therapy. Whole genome sequencing of the virus showed Pango lineage B.1.221. Between the first sample and the second from bronchoalveolar lavage fluid 7 weeks later, we identified eight mutations, including minor variants, which could be used to estimate the chronology of mutations. This suggests an elevated mutation rate, in-host accumulation of mutations and further evidence for sources of VoCs. Prolonged SARS-CoV-2 infections in immunocompromised hosts increase the likelihood of hospital stays and morbidity, and also pose an increased risk to global public health.

Indexed as

COVID-19SARS-CoV-2COVID-19 SerotherapyGenome, ViralHumansImmunization, PassiveImmunocompromised HostMaleMutationWhole Genome SequencingCOVID-19Drugs: infectious diseasesHaematology (incl blood transfusion)Immunological products and vaccinesPublic health

Identifiers

PMID38087481
PMCPMC10728978

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.